CEO Matt Gline is juggling Roivant Sciences’ first solo drug launch and several maturing programs as the hub-and-spoke company sets its sights on a massive turning point into commercial viability.
Roivant, the ‘inveterate drug hunters’, enters commercial era with Lisraya